← All industries · Healthcare

Industry

Medical Labs

Every analyzed stock in Medical Labs — 28 companies. Each card shows price, our model's intrinsic value (IV), and how far price sits above or below it. Click any card for the full analysis. This is a research-triage view, not a buy/sell signal.

Educational use only — not investment advice. "Undervalued / fairly valued / overvalued" and every risk score reflect our models vs. price, which can be wrong or based on stale or incomplete data. Always review the company's own financials and SEC filings, and consult a licensed advisor, before acting.

Sort by: A–Z Most overvalued Most shorted Buyers' strike Largest

Market implies +31.3%/yr

Deeply undervalued

Discount 65% Return to IV: +184.4%

Market implies -25.0%/yr vs model +5.9% · below model

Advanced Biomed Inc.

Limited data — see page

AMERICAN SHARED HOSPITAL SERVICES

Deeply undervalued

Discount 63% Return to IV: +168.4%

Market implies -21.1%/yr vs model +12.4% · below model

Deeply overvalued

Premium +145% Return to IV: -59.1%

Market implies +10.3%/yr vs model +12.9% · in line

BioNexus Gene Lab Corp

Deeply overvalued

Premium +135% Return to IV: -57.4%

Market implies +10.4%/yr vs model +2.0% · above model

BillionToOne, Inc.

Premium +4% Return to IV: -3.5%

Market implies +1.4%/yr vs model +50.0% · below model

Burning Rock Biotech Ltd

Deeply overvalued

Premium +292% Return to IV: -74.5%

Market implies +20.7%/yr vs model +2.0% · above model

Caris Life Sciences, Inc.

Deeply undervalued

Discount 34% Return to IV: +50.5%

Market implies -6.2%/yr vs model +50.0% · below model

Deeply overvalued

Premium +427% Return to IV: -81.0%

Market implies +20.3%/yr vs model +6.4% · above model

Limited data — see page

CASTLE BIOSCIENCES INC

Deeply undervalued

Discount 52% Return to IV: +108.9%

Market implies -16.3%/yr vs model +38.3% · below model

QUEST DIAGNOSTICS INC

Model IV$263.38

Discount 12% Return to IV: +14.1%

Market implies +4.2%/yr vs model +7.2% · in line

Fulgent Genetics, Inc.

Deeply overvalued

Premium +152% Return to IV: -60.4%

Market implies +8.3%/yr vs model +2.0% · above model

Fortrea Holdings Inc.

Premium +8% Return to IV: -7.6%

Market implies +6.0%/yr vs model +2.0% · above model

Guardant Health, Inc.

Deeply overvalued

Premium +492% Return to IV: -83.1%

Market implies +20.3%/yr vs model +27.3% · below model

Market implies +49.1%/yr

LABCORP HOLDINGS INC.

Model IV$397.08

Discount 21% Return to IV: +26.4%

Market implies +3.4%/yr vs model +7.8% · below model

Lumexa Imaging Holdings, Inc.

Limited data — see page

Deeply undervalued

Discount 90% Return to IV: +892.8%

Market implies -46.9%/yr vs model +48.4% · below model

Deeply overvalued

Premium +319% Return to IV: -76.1%

Market implies +17.8%/yr vs model +38.6% · below model

Perceptive Capital Solutions Corp

Limited data — see page

Personalis, Inc.

Market implies +78.1%/yr

Premium +1% Return to IV: -1.4%

Market implies -2.8%/yr vs model +11.6% · below model

SERA PROGNOSTICS, INC.

Market implies +116.1%/yr vs model +2.0% · above model

Deeply overvalued

Premium +89% Return to IV: -47.1%

Market implies +20.0%/yr vs model +14.2% · above model

Deeply overvalued

Premium +325% Return to IV: -76.5%

Market implies +18.8%/yr vs model +8.4% · above model

Market implies +49.4%/yr vs model +30.6% · above model